Table 2.

Effect of IFN-α2/α1 Treatment on Lymphoid, Myeloid, and Erythroid Development in Bone Marrow and Spleen

Treatment*		Bone marrow						Spleen
		B220+		Mac-1+		Ter119+		B220+		Mac-1+		Ter119+
PBS		21.8 ± 1.8‡		23.3 ± 3.0		40.3 ± 1.6		11.0 ± 2.7		3.6 ± 0.4		69.7 ± 8.4
IFNα2/α1		8.7 ± 0.9§		26.9 ± 2.6		26.4 ± 4.5§		6.0 ± 0.5§		7.4 ± 0.4§		45.8 ± 3.4§

^* Peritoneal injections of PBS or IFN-α2/α1 (4 × 10⁵ U) were administered daily from 3–8 d of age and the mice were killed at 9 d of age.  

^‡ Mean percentage of marker-positive cells ±1 SE for six mice.  

^§  P ⩽0.01, unpaired Student's t test.